Avelumab (anti-PD-L1)

Catalog No.A2015 Batch: A201505

Technical Data

CAS No.	1537032-82-8
Formulation	100 mM Pro-Ac, 20 mM Arg, pH 5.0
Isotype	Human IgG1
Source	Human
Storage (From the date of receipt)	Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles
Purity	99%
Protein concentration	5.585

Biological Activity

Description	Avelumab (anti-PD-L1) (MSB0010718C) is a fully human IgG1 monoclonal antibody that targets the protein programmed death-ligand 1 (PD-L1). Avelumab exhibits potential antibody-dependent cell-mediated cytotoxicity and is used for the treatment of several kinds of carcinoma. MW=143.8 kDa.
In vitro	Co-incubating chordoma cells with brachyury-specific CD8+ T cells results in significant upregulation of PD-L1 on the tumor cells, mediated by the CD8+ T cells' IFN-γ production, and increases sensitivity of chordoma cells to avelumab-mediated ADCC. Residential cancer stem cell subpopulations of chordoma cells are also killed by avelumab-mediated ADCC to the same degree as non-cancer stem cell populations. As a monotherapy for chordoma, avelumab may enable endogenous NK cells, while in combination with T-cell immunotherapy, such as a vaccine, avelumab may enhance NK-cell killing of chordoma cells via ADCC.^[1]
In vivo	An aggressive, bioluminescent orthotopic bladder cancer model, MB49 tumor cells transfected with luciferase (MB49^luc) is used to study the antitumor effects of avelumab. MB49^luc bladder tumors are highly positive for the expression of PD-L1 and avelumab administration induces significant (P<0.05) antitumor effects.^[2]

Protocol (Only for Reference)

Cell Assay:	Objective: Antibody-dependent cellular cytotoxicity assay Cells: UM-Chor1 cells Concentrations: 2 μg/mL Incubation Time: 30 min Method: To examine the relationship between a CSC subpopulation and ADCC activity, UM-Chor1 cells are left untreated or treated with 50 ng/mL of IFN-γ for 24 h. Cells are then plated as targets at 50,000 cells/well in 6-well round-bottom culture plates and incubated with 2 μg/mL of avelumab at room temperature for 30 min. NK cells are added at 2500,000 cells/well at an E:T ratio of 50:1. After 4 h, tumor cells are harvested and stained with antibodies for flow cytometry. Reference: https://pubmed.ncbi.nlm.nih.gov/27172898 Avelumab can apply to humanized mice, non-humanized mice (eg: C57BL/6 mice), peripheral blood and other related assays (Only for Reference)
Animal Study:	Objective: Measurement of individual tumors Animal Models: 16- to 18-week-old female C57BL/6 mice Formulation: DPBS Dosages: 400 μg/100 μL Administration: i.p. Reference: https://pubmed.ncbi.nlm.nih.gov/26921031/ Avelumab can apply to humanized mice, non-humanized mice (eg: C57BL/6 mice), peripheral blood and other related assays (Only for Reference)

Cell Assay:

Objective: Antibody-dependent cellular cytotoxicity assay
Cells: UM-Chor1 cells
Concentrations: 2 μg/mL
Incubation Time: 30 min
Method: To examine the relationship between a CSC subpopulation and ADCC activity, UM-Chor1 cells are left untreated or treated with 50 ng/mL of IFN-γ for 24 h. Cells are then plated as targets at 50,000 cells/well in 6-well round-bottom culture plates and incubated with 2 μg/mL of avelumab at room temperature for 30 min. NK cells are added at 2500,000 cells/well at an E:T ratio of 50:1. After 4 h, tumor cells are harvested and stained with antibodies for flow cytometry.
Reference: https://pubmed.ncbi.nlm.nih.gov/27172898

Avelumab can apply to humanized mice, non-humanized mice (eg: C57BL/6 mice), peripheral blood and other related assays (Only for Reference)

Animal Study:

Objective: Measurement of individual tumors
Animal Models: 16- to 18-week-old female C57BL/6 mice
Formulation: DPBS
Dosages: 400 μg/100 μL
Administration: i.p.
Reference: https://pubmed.ncbi.nlm.nih.gov/26921031/

Avelumab can apply to humanized mice, non-humanized mice (eg: C57BL/6 mice), peripheral blood and other related assays (Only for Reference)

References	[1] Rika Fujii, et al. Oncotarget. 2016 Jun 7;7(23):33498-511. [2] Amanda J Vandeveer, et al. Cancer Immunol Res. 2016 May;4(5):452-62.

References

Customer Product Validation

Selleck's Avelumab (anti-PD-L1) has been cited by 2 publications

Polymer-based antibody mimetics (iBodies) target human PD-L1 and function as a potent immune checkpoint blocker [ J Biol Chem, 2024, S0021-9258(24)01826-X]	PubMed: 38685532
TNF-Mediated Inhibition of Classical Swine Fever Virus Replication Is IRF1-, NF-κB- and JAK/STAT Signaling-Dependent [ Viruses, 2021, 13(10)2017]	PubMed: 34696447

FOR RESEARCH USE ONLY. NOT FOR USE IN HUMANS.

Specific storage and handling information for each product is indicated on the product datasheet. Most Selleck products are stable under the recommended conditions. Products are sometimes shipped at a temperature that differs from the recommended storage temperature. Short-term storage of many products are stable in the short-term at temperatures that differ from that required for long-term storage.
We ensure that the product is shipped under conditions that will maintain the quality of the reagents. Upon receipt of the product, follow the storage recommendations on the product data sheet.